晚期胰腺癌介入治疗临床操作指南(试行)(第三版)

中国癌症研究基金会介入医学委员会,中国介入医师分会介入医学与生物工程委会

doi:10.3969/j.issn.1001-5256.2019.04.009

晚期胰腺癌介入治疗临床操作指南(试行)(第三版)

DOI: 10.3969/j.issn.1001-5256.2019.04.009

中国癌症研究基金会介入医学委员会,中国介入医师分会介入医学与生物工程委会

详细信息

中图分类号: R735.9
计量
- 文章访问数: 724
- HTML全文浏览量: 40
- PDF下载量: 504
- 被引次数: 0
出版历程
- 出版日期: 2019-04-20

Clinical practice guidelines for the interventional treatment of advanced pancreatic carcinoma (on trial) (3rd edition)

Committee of Interventional MedicineCancer Foundation of China;Committee of Interventional Medicine and BioengineeringChinese Society of Interventional Physicians;

摘要

摘要:
<正>1晚期胰腺癌的定义本指南所指晚期胰腺癌为胰腺导管细胞癌,已发生局部和(或)远处转移,无法进行外科手术切除[1],TNM分期在T3N0M0以上,具体分期见表1。胰腺癌是常见消化系统恶性肿瘤之一,全国肿瘤登记中心(NCCR)在《CA:A Cancer Journal for Clinicians》杂志上发表了2015年中国癌症统计数据,估计中国2015年新增430万癌症
- 胰腺肿瘤 /
- 介入治疗 /
- 诊疗准则
- pancreatic neoplasms /
- interventional treatment /
- practice guideline

HTML全文

参考文献(64)

[1]AMIN MB, GREENE FL, EDGE SB, et al. The Eighth Edition AJCC Cancer Staging Manual:Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging[J]. CA Cancer J Clin, 2017, 67 (2) :93-99.

[2]SOBIN LH, GOSPODAROWICZ MK, WITTEKIND C, et al. TNM classification of malignant tumours[M]. 7th ed. Chichester, West Sussex, UK; Hoboken, NJ:Wiley-Blackwell, 2010.

[3]CHEN WQ, ZHENG RS, BAADE PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66 (1) :115-132.

[4]FURUKAWA H, OKADA S, SAISHO H, et al. Clinicopathologic features of small pancreatic adenocarcinoma[J]. A collective study, Cancer, 1996, 78 (5) :986-990.

[5]HIDAGOM M. Pancreatic cancer[J]. N Engl J Med, 2010, 362 (17) :1605-1617.

[6]BRUGGE WR. Endoscopic ultrasonography:The current status[J]. Gastroenterology, 1998, 115 (6) :1577-1583.

[7]Pancreatic Cancer Committee of Chinese Anti-Cancer Association. Comprehensive guidelines for the diagnosis and treatment of pancreatic cancer (2018 version) [J]. J Clin Hepatol, 2018, 34 (10) :2109-2120. (in Chinese) 中国抗癌协会胰腺癌专业委员会.胰腺癌综合诊治指南 (2018版) [J].临床肝胆病杂志, 2018, 34 (10) :2109-2120.

[8] Study Group of Pancreatic Surgery in Chinese Society of Surgery of Chinese Medical Association, Pancreatic Disease Committee of Chinese Research Hospital Association, Editorial Board of Chinese Journal of Surgery. A consensus statement on the diagnosis, treatment, and prevention of common complications after pancreatic surgery (2010) [J]. Chin J Surg, 2010, 48 (18) :1365-1368. (in Chinese) 中华医学会外科学分会胰腺外科学组, 中国研究型医院学会胰腺病专业委员会, 中华外科杂志编辑部.胰腺术后外科常见并发症预防及治疗的专家共识 (2010) [J].中华外科杂志, 2010, 48 (18) :1365-1368.

[9]NI QX, YU XR, LIU L. Discussion for the clinical definition of pancreatic cancer in China[J]. China Oncol, 2012, 22 (2) :81-87. (in Chinese) 倪泉兴, 虞先濬, 刘亮.中国胰腺癌临床诊断标准的探讨[J].中国癌症杂志, 2012, 22 (2) :81-87.

[10]KIRTLAND HB Jr. A safe method of pancreatic biopsy; a preliminary report[J]. Am J Surg, 1951, 82 (4) :451-457.

[11]SMITH EH, BARTRUM RJ Jr, CHANG YC. Ultrasonically guided percutaneous aspiration biopsy of the pancreas[J].Radiology, 1974, 112 (3) :737-738.

[12]LNING M, KURSAWE R, SCHPKE W, et al. CT guided percutaneous fine-needle biopsy of the pancreas[J]. Eur J Radiol, 1985, 5 (2) :104-108.

[13]D'ONOFRIO M, MALAGR, ZAMBONI G, et al. Ultrasonography of the pancreas Interventional procedures[J]. Abdom Imaging, 2007, 32 (2) :182-190.

[14]RAYMOND SLT, YUGAWA D, CHANG KHF, et al. Metastatic neoplasms to the pancreas diagnosed by fine-needle aspiration/biopsy cytology:A 15-year retrospective analysis[J].Diagn Cytopathol, 2017, 45 (9) :771-783.

[15]NCCN Guidelines for Pancreatic Adenocarcinoma. https://www.nccn. org/professionals/physician_gls/default. aspx#pancreatic

[16]SHI HB, YANG MJ, WANG XL, et al. Feeding arteries of advanced pancreatic cancer:Evaluation of 218 patients by digital subtract angiography[J]. Clin Med J China, 2014, 21 (1) :61-62. (in Chinese) 施惠斌, 杨敏捷, 王小林, 等.晚期胰腺癌患者的肿瘤血供来源:218例患者的DSA评价[J].中国临床医学, 2014, 21 (1) :61-62.

[17]RUARUS A, VROOMEN L, PUIJK R, et al. Locally advanced pancreatic cancer:A review of local ablative therapies[J].Cancers, 2018, 10 (1) :1-18.

[18]HESS V, GLIMEUS B, GRAWE P, et al. CA19-9 tumourmarker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial[J]. Lancet Oncol, 2008, 9 (2) :132-138.

[19]MAITHELS K, MALONEY S, WINSTON C, et al. Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma[J].Ann Surg Oncol, 2008, 15 (12) :3512-3520.

[20]TAKAHASHI H, OHIASHI H, ISHIKAWA O, et al. Serum CA19-9 alterations during preoperative gemcitabinebased chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival[J]. Ann Surg, 2010, 251 (3) :461-469.

[21]GOONNETILLEKE KS, SIRWARDENA AK. Systematic review of carbohydrate antigen (CA19-9) as a biochemical marker in the diagnosis of pancreatic cancer[J]. Eur J Surg Oncol, 2007, 33 (3) :266-270.

[22]TEMPERO MA, MALAFA MP, MAL-HAWARY, et al. NCCN Guidelines Version 2. 2016 Pancreatic Adenocarcinoma Version 2. 2016, 08/16/16National Comprehensive Cancer Network, Inc. 2016.

[23]NIMURA Y, NAGINO M, TAKAO S, et al. Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas. Long-term results of a Japanese multicenter randomized controlled trial[J]. J Hepatobiliary Pancreatic Sci, 2012, 19 (3) :230-241.

[24]JANG JY, KANG MJ, HEO JS, et al. A prospective randomized controlled study comparing outcomes of standard resection and extended resection, including dissection of the nerve plexus and various lymph nodes, in patients with pancreatic head cancer[J]. Ann Surg, 2014, 259 (4) :656-664.

[25]SIEGEL R, MA J, ZOU Z, et al. Cancer statistics, 2014[J].CA Cancer J Clin, 2014, 64 (1) :9-29.

[26]National Cancer Network. Clinical Practice Guidelines in Oncology. Pancreatic Adenocarcinoma. Version 2. 2014. Available from:http://www. nccn. org/professionals/physician_gls/f_guidelines. asp.

[27]TOL JAM, GOUMA DJ, BASSI C, et al. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma:A consensus statement by the International Study Group on Pancreatic Surgery (ISGPS) [J]. Surgery, 2014, 156 (3) :591-600.

[28]BOCKHORN M, UZUNOGLU FG, ADHAM M, et al. Borderline resectable pancreatic cancer:A consensus statement by the International Study Group of Pancreatic Surgery (ISGPS) [J]. Surgery, 2014, 155 (6) :977-988.

[29]HARTWIG W, VOLLMER CM, FINGERHUT A, et al. Extended pancreatectomy in pancreatic ductal adenocarcinoma:Definition and consensus of the International Study Group for Pancreatic Surgery (ISGPS) [J]. Surgery, 2014, 156 (1) :1-14.

[30]ASBUN HJ, CONLON K, FERNANDEZ-CRUZ L, et al. When to performance pancreatoduodenectomy in the absence of positive histology? A consensus statement by the International Study Group of Pancreatic Surgery[J]. Surgery, 2014, 155 (5) :887-892.

[31]Interventional Organization, Radiology Branch, Chinese Medical Association. Guide to intra-arterial infusion chemotherapy for pancreatic cancers (draft text) [J]. J IntervenRadiol, 2012, 21 (5) :353-355. (in Chinese) 中华医学会放射学分会介入学组.胰腺癌经动脉灌注化疗指南 (草案) [J].介入放射学杂志, 2012, 21 (5) :353-355.

[32]Japan Pancreas Society. Classification of pancreatic carcinoma[M]. Second English ed, Tokyo:Kanehara&Co, Ltd, 2003.

[33]PHILIP PA, BENEDETTI J, CORLESS CL, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma:Southwest Oncology Group directed intergroup trial S0205[J]. J Clin Oncol, 2010, 28 (22) :3605-3610.

[34]KINDLER HL, NIEDZWIECKI D, HOLLIS D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer:PhaseⅢtrial of the Cancer and Leukemia Group B (CALGB 80303) [J]. J Clin Oncol, 2010, 28 (22) :3617-3622.

[35]MOORE MJ, GOLDSTEIN D, HAMM J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer:A phase III trial of the National Cancer Institute of Canada Clinical Trials Group[J]. J Clin Oncol, 2007, 25 (15) :1960-1966.

[36]TANAKA T, SAKAGUCHI H, SHO M, et al. A novel interventional radiology technique for arterial infusion chemotherapy against advanced pancreatic Cancer[J]. AJR, 2009, 192 (2) :168-177.

[37]CONROY T, DESSEIGNE F, YCHOU M, et al. Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer[J]. N Engl J Med, 2011, 364 (19) :1817-1825.

[38]KULKE MH, TEMPERO MA, NIEDZWIECKI D, et al. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer:CALGB89904[J]. J Clin Oncol, 2009, 27 (33) :5506-5512.

[39]CUNNINGHAM D, CHAU I, STOCKEN DD, et al. PhaseⅢrandomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer[J]. J Clin Oncol, 2009, 27 (33) :5513-5518.

[40]LOUVET C, LABIANCA R, HAMMEL P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer:Results of a GERCOR and GISCAD phaseⅢtrial[J]. J Clin Oncol, 2005, 23 (15) :3509-3516.

[41]OETTLE H, RICHARDS D, RAMANATHAN RK, et al. A phaseⅢtrial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer[J]. Ann Oncol, 2005, 16 (10) :1639-1645.

[42]ABOU-ALFA GK, LETOURNEAU R, HARKER G, et al. Randomized phaseⅢstudy of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer[J]. J Clin Oncol, 2006, 24 (27) :4441-4447.

[43]TEMPERO M, PLUNKETT W, RUIZ VAN HAPEREN V, et al.Randomized phaseⅡcomparison of dose-intense gemcitabine:Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma[J]. J Clin Oncol, 2003, 21 (18) :3402-3408.

[44]MENON KV, GOMEZ D, SMITH AM, et al. Impact of margin status on survival following pancreatoduo-denectomy for cancer:The leeds pathology protocol (LEEPP) [J]. HPB (Oxford) , 2009, 11 (1) :18-24.

[45]XU YC, ZHAO TJ, QIAO ZF, et al. CT-guided percutaneous implantation of125I seed for carcinoma of head of pancreas[J]. Chin J Min Inv Surg, 2013, 13 (10) :865-868. (in Chinese) 徐元昌, 赵铁军, 乔占峰, 等. CT引导经皮穿刺125I粒子植入治疗胰头癌[J].中国微创外科杂志, 2013, 13 (10) :865-868.

[46]FUJII T, SATOI S, YAMADA S, et al. Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head:An observational study using inverse probability of treatment weighting[J]. J Gastroenterol, 2017, 52 (1) :81-93.

[47]LUNDIN J, ROBERTS PJ, KUUSELA P, et al. Prognostic significance of serum CA242 in pancreatic cancer. A comparison with CA19-9[J]. Anticancer Res, 1995, 15 (5) :2181-2186.

[48]YU BF, SINIL K. Alcohol with in tratumoral drug in jection and pharmacokinetics of drug after intratumoral injection:A new concept of intratumoral autologous therapeutic coagulum with drug depots introduction[J]. J Current Oncology, 1994, 1 (2) :97-100. (in Chinese) 于保法, Sinil Kim.抗癌药物酒精饱和液肿瘤内注射疗法及其药物动力学研究—一种肿瘤自身治疗性凝固块作为抗癌药物缓释库的新概念[J].当代肿瘤学杂志, 1994, 1 (2) :97-100.

[49]PU JQ, YU BF. Slow intra-tumor release of drugs on B16melonoma in mice[J]. J Shandong Univ:Health Sciences, 2007, 45 (10) :988-991. (in Chinese) 卜洁琼, 于保法.瘤内缓释治疗对B16黑色素瘤小鼠影响的实验研究[J].山东大学学报:医学版, 2007, 45 (10) :988-991.

[50]YU BF. Interventional oncology&chemoimmunotherapy[M].Beijing:Military Medical Science Press, 2014:92429. (in Chinese) 于保法.肿瘤介入化学免疫治疗学[M].北京:军事医学科学出版社, 2014:92429.

[51]CAI P, CHEN GM, YANG XG, et al. Clinical efficacy of local hyperthermia in the treatment of advanced pancreatic cancer[J]. Mod Oncol, 2015, 23 (5) :655-657. (in Chinese) 蔡鹏, 陈桂明, 杨先国, 等.局部热恋联合化疗治疗晚期胰腺癌的疗效观察[J].现代肿瘤医学, 2015, 23 (5) :655-657.

[52]ZONG Y, NI SX, ZHANG XQ. Clinical analysis of oxaliplatin treatment for the advanced pancreatic cancer through regional arterial infusion chemotherapy[J]. Pract Pharm Clin Remedies, 2013, 16 (4) :284-285. (in Chinese) 宗煜, 倪绍祥, 张宪庆.奥沙利铂经区域性动脉灌注化疗治疗晚期胰腺癌临床分析[J].实用药物与临床, 2013, 16 (4) :284-285.

[53]REN XH, LIU L, LIU PP, et al. Changes of T lymphocyte subgroups in cancer patients and its relationship with tumor staging[J]. J Third Milit Med Univ, 2006, 28 (18) :1906-1908. (in Chinese) 任秀红, 刘莉, 刘平平, 等.恶性肿瘤患者T细胞亚群变化及其与肿瘤分期的关系[J].第三军医大学学报, 2006, 28 (18) :1906-1908

[54]BALZANO G, di CARLO V. Is CA19-9 useful in the management of pancreatic cancer?[J]. Lancet Oncol, 2008, 9 (2) :89-91.

[55]LIU LX, WANG JH, WANG XL, et al. Treatment of advanced pancreatic cancer by transarterial infusion of gemcitabine[J].Chin Comput Med Imag, 2007, 13 (3) :202-207. (in Chinese) 刘凌晓, 王建华, 王小林, 等.中晚期胰腺癌动脉灌注吉西他滨化疗的疗效分析[J].中国医学计算机成像杂志, 2007, 13 (3) :202-207.

[56]SHI HF, JIN ZY, ZHOU ZQ, et al. Transarterial infusion chemotherapy with a combination of gemcitabine and 5-fluorouracil in advanced pancreatic carcinoma[J]. Chin J Radiol, 2002, 36 (12) :1072-1074. (in Chinese) 石海峰, 金征宇, 周智强, 等.经动脉灌注盐酸吉西他滨和5-氟尿嘧啶治疗中晚期胰腺癌的疗效分析[J].中华放射学杂志, 2002, 36 (12) :1072-1074.

[57]HUANG J, TIAN DG, ZHAGN J, et al. Therapeutic effects of gemcitabine regional artery perfusion combined with systemic chemotherapy for late-stage cancer of pancreas[J]. Chin J Gen Surg, 2007, 16 (5) :471-473. (in Chinese) 黄洁, 田大广, 张捷, 等.吉西他滨区域性动脉灌注联合全身化疗治疗晚期胰腺癌[J].中国普通外科杂志, 2007, 16 (5) :471-473.

[58]HAN SL, CAO CW, TANG T, et al. ROBO3 promotes growth and metastasis of pancreatic carcinoma[J]. Cancer Lett, 2015, 366 (1) :61-70.

[59]LIU T, WU GY, CHENG JJ, et al. Multifunctional lymph-targeted platform based on Mn@mSiO2 nanocomposites:Combining PFOB for dual-mode imaging and DOX for cancer diagnose and treatment[J]. Nano Research, 2016, 9 (2) :473-489.

[60]LIU LX, WANG JH, WANG XL, et al. A retrospective analysis of patients with unresectable pancreatic cancer treated with combined transarterial intervention and three dimensional conformal radiotherapy[J]. China Oncol, 2011, 21 (1) :46-51. (in Chinese) 刘凌晓, 王建华, 王小林, 等.介入治疗联合三维适形放疗治疗不能手术切除的胰腺癌患者疗效分析[J].中国癌症杂志, 2011, 21 (1) :46-51.

[61]VINCENT A, HERMAN J, SCHULICK R, et al. Pancreatic cancer[J]. Lancet, 2011, 378 (9791) :607-620.

[62]KHORANA AA, MANGU PB, BERLIN J, et al. Potentially curable pancreatic cancer:American society of clinical oncology clinical practice guideline update[J]. J Clin Oncol, 2017, 35 (20) :2324-2328.

[63]BERGER AC, GARCIA M JR, HOFFMAN JP, et al. Postresection CA19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation:A prospective validation by RTOG 9704[J]. J Clin Oncol, 2008, 26 (36) :5918-5922.

[64]CHEN Y, WANG XL, WANG JH, et al. Transarterial infusion with gemcitabine and oxaliplatin for the treatment of unresectable pancreatic cancer[J]. Anticancer Drugs, 2014, 25 (8) :958-963.

施引文献

资源附件(0)

访问统计